Vor Biopharma VOR

$ 0.71 -3.54%

Quarterly report 2024-Q2
added 08-08-2024

Vor Biopharma Balance Sheet 2011-2024 | VOR

Annual Balance Sheet Vor Biopharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	4.3 M	-18.8 M	-102 M	-30.2 M	-6.47 M	3.53 M	-	-	-	-	-	-	-
Long Term Debt	31.8 M	35.6 M	16.2 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	3.83 M	3.27 M	1.84 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	17.4 M	25.1 M	2 K	-	-	-	-	-	-	-
Total Current Liabilities	15.6 M	13.1 M	10.2 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	47.4 M	48.8 M	26.3 M	27.6 M	27.3 M	7.78 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-340 M	-222 M	-130 M	-61.2 M	-17.9 M	-7.05 M	-	-	-	-	-	-	-
Total Assets	198 M	299 M	243 M	75.9 M	9.83 M	1.01 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	31.4 M	57.7 M	120 M	-	-	-	-	-	-	-	-	-	-
Book Value	151 M	251 M	216 M	48.3 M	-17.4 M	-6.77 M	-	-	-	-	-	-	-
Total Shareholders Equity	151 M	251 M	216 M	-59.1 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Vor Biopharma

	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	29.7 M	31.8 M	32.9 M	33.8 M	34.7 M	35.6 M	36.5 M	37.4 M	21.7 M	16.2 M	16.5 M	16.7 M	17.1 M	17.4 M	17.4 M	17.4 M	17.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	43.5 M	47.4 M	48.2 M	46.5 M	47.3 M	48.8 M	47.6 M	49.6 M	39.8 M	26.3 M	25.7 M	25 M	25.8 M	27.6 M	27.6 M	27.6 M	27.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-399 M	-340 M	-314 M	-281 M	-251 M	-222 M	-198 M	-175 M	-153 M	-130 M	-112 M	-93.3 M	-74.9 M	-61.2 M	-61.2 M	-61.2 M	-61.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	142 M	198 M	223 M	251 M	278 M	299 M	206 M	225 M	234 M	243 M	259 M	275 M	293 M	75.9 M	75.9 M	75.9 M	75.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	76.1 M	31.4 M	45 M	32.2 M	42.5 M	57.7 M	60.8 M	63 M	90 M	120 M	143 M	170 M	263 M	48.5 M	48.5 M	48.5 M	48.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	98.1 M	151 M	175 M	204 M	230 M	251 M	159 M	175 M	194 M	216 M	233 M	250 M	267 M	48.3 M	48.3 M	48.3 M	48.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	98.1 M	151 M	175 M	204 M	230 M	251 M	159 M	175 M	194 M	216 M	233 M	250 M	267 M	-59.1 M	-59.1 M	-59.1 M	-59.1 M	-17.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency